Awakn Life Sciences Corp.

CNSX:AWKN Stock Report

Market Cap: CA$4.6m

Awakn Life Sciences Past Earnings Performance

Past criteria checks 0/6

Awakn Life Sciences has been growing earnings at an average annual rate of 37%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 47.5% per year.

Key information

37.0%

Earnings growth rate

47.6%

EPS growth rate

Biotechs Industry Growth51.1%
Revenue growth rate-47.5%
Return on equityn/a
Net Margin-3,479.8%
Last Earnings Update31 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Awakn Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:AWKN Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jul 240-321
30 Apr 240-431
31 Jan 240-431
31 Oct 230-341
31 Jul 230-341
30 Apr 230-331
31 Jan 230-541
31 Oct 220-853
31 Jul 220-1063
30 Apr 220-1874
31 Jan 220-1663
31 Oct 210-1342

Quality Earnings: AWKN is currently unprofitable.

Growing Profit Margin: AWKN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AWKN is unprofitable, but has reduced losses over the past 5 years at a rate of 37% per year.

Accelerating Growth: Unable to compare AWKN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AWKN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: AWKN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies